ArticleInternational journal of retina and vitreous2025
Correlation of retinal thickness, macular volume, and their fluctuation with visual outcomes in patients with macular edema due to retinal vein occlusion.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to examine the utility of macular volume (MV), central retinal thickness (CRT), and their fluctuations for predicting post-treatment visual acuity in patients with macular edema (ME) secondary to retinal vein occlusion (RVO).
methodsThis retrospective cohort study included patients treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for ME due to RVO at a tertiary university hospital between August 2016 and July 2020. We identify the correlation of the MV, CRT, with their fluctuations, and best-corrected visual acuity (BCVA) measured using optical coherence tomography at baseline and at 1-, 3-, 6-, and 12-months post-treatment.
resultsAmong the 74 eyes included, 27 and 47 had central RVO (CRVO) and branch RVO (BRVO), respectively. Following anti-VEGF therapy both, the CRVO and BRVO group exhibited significant improvements in BCVA, CRT, and MV compared to baseline. In all patients, MV was consistently correlated with BCVA, whereas CRT was correlated with BCVA at selected time points. In patients with CRVO, MV was a better predictor of post-treatment visual outcomes than CRT. Moreover, fluctuations in CRT and MV correlated with BCVA over 12 months.
conclusionsMV yielded more correlation with visual outcomes in patients with RVO and ME receiving anti-VEGF therapy than CRT. Considering concurrent MV and CRT measurements could enhance more precision of treatment assessment, especially in CRVO patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.